Biotech news
Americas
The US Court of Appeals for the Federal Circuit erred in holding that biosimilar applicants must give 180 days’ pre-marketing notice after an application has been approved by the US Food and Drug Administration, according to the acting solicitor general. 28 February 2017
Pharma
“The Unified Patent Court without Britain is a far less potent idea,” says Nick McDonald, partner of Potter Clarkson. 28 February 2017
Biotech
According to the European Commission, if a biotech company crosses two plants to create a new plant through natural means, the outcome will not be patentable, explains Jane Wainwright of Potter Clarkson in a video interview with LSIPR. 23 February 2017
Biotech
European Council members exchanged views on IP at the Competitiveness Council this week, agreeing that IP is one of the drivers of productivity and economic growth for companies. 22 February 2017
Americas
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), has filed a brief in support of Sandoz’s petition for certiorari in the pending Sandoz v Amgen case. 22 February 2017
Asia
Danish biotechnology company Novozymes has won a patent dispute against China-based enzyme makers Shandong Longda Bio-Products and Jiangsu Boli Bioproducts at the Supreme People’s Court of China. 21 February 2017
Americas
Anyone drafting patent licence agreements should follow several tips in order to avoid or better prepare for litigation later on, says Jessamyn Berniker of Williams & Connolly. 21 February 2017
Americas
A scientist in Kansas has been convicted for conspiring to steal samples of genetically engineered rice seeds from a US biopharmaceutical research facility, Ventria Bioscience. 20 February 2017
Americas
Although the Patent Trial and Appeal Board gave a win to The Broad Institute of Harvard and MIT in the CRISPR patent conflict against the University of California, Berkeley and the University of Vienna, lawyers say the dispute may still not be resolved. 17 February 2017
Americas
Amgen has been accused of withholding confidential information about its proposed biosimilar of Genentech’s cancer drug Avastin. 17 February 2017